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Skeletal muscle tissue is characterized by high metabolic requirements, defined structure
and high regenerative potential. As such, it constitutes an appealing platform for tissue
engineering to address volumetric defects, as proven by recent works in this field. Several
issues common to all engineered constructs constrain the variety of tissues that can be
realized in vitro, principal among them the lack of a vascular system and the absence
of reliable cell sources; as it is, the only successful tissue engineering constructs are
not characterized by active function, present limited cellular survival at implantation and
possess low metabolic requirements. Recently, functionally competent constructs have
been engineered, with vascular structures supporting their metabolic requirements. In
addition to the use of biochemical cues, physical means, mechanical stimulation and the
application of electric tension have proven effective in stimulating the differentiation of
cells and the maturation of the constructs; while the use of co-cultures provided fine
control of cellular developments through paracrine activity. This review will provide a
brief analysis of some of the most promising improvements in the field, with particular
attention to the techniques that could prove easily transferable to other branches of tissue
engineering.
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INTRODUCTION
Skeletal muscle tissue represents the most abundant tissue type in
the human body, amounting to 60% of the average weight. It is
a metabolically active tissues requiring a constant flow of nutri-
ents and metabolites, provided by an extensive capillary network
forming an organized branching pattern throughout the fibers
(Dennis and Kosnik, 2000; Liu et al., 2012).
Skeletal muscle tissue engineering (SMTE) aims to replicate
the structure and function of skeletal muscle tissue in vitro
and in vivo, to obtain valid models and functional constructs
whose ultimate goal is the implantation as a therapeutic device
(Ostrovidov et al., 2014). This discipline presents unique chal-
lenges compared to other tissue engineering strategies that have
shown promise in clinical applications (Naito et al., 2003; Atala
et al., 2006; Macchiarini et al., 2008; McAllister et al., 2009), in
that small lesions and defects in skeletal muscle tissue seldom, if at
all, require chirurgical intervention and transplantation; injuries
heal spontaneously through an inflammation related mechanism
(Ciciliot and Schiaffino, 2010; Turner and Badylak, 2012) involv-
ing resident stem cells, named satellite cells (SCs) (Pannérec et al.,
2012).
Lesions so extensive that the function of themuscle is impaired
are commonly designated volumetric muscle losses (VMLs)
(Grogan et al., 2011); these lesions, mainly due to traumatic
injury and chirurgical resection of tumors, are treated using free
standing flaps as gold standard, a procedure that is inevitably
associated with morbidity at the donor site and limited success-
ful outcomes (Agostini et al., 2013). The use of flaps, rather than
grafts, is a necessity because transplants of this kind cannot sur-
vive without an independent blood supply Similarly, clinically
relevant SMTE constructs would require autonomous vascular
networks to avoid central (Griffith et al., 2005; Bae et al., 2012;
Shandalov et al., 2014).
However, in a clinical setting the goal of an SMTE device is
the reestablishment of function rather than the original home-
ostasis of the tissue, there have been efforts to engineer constructs
in which the contractile ability of the muscles is restored through
functional fibrotic structures (Corona et al., 2013b); as long as
there is a continuity in muscle architecture that allows the force
transmission even a fibrotic structure formed from and acellular
scaffold will ameliorate VML (Aärimaa et al., 2004).
Given the unique requirements in the treatment of the lesions
in musculoskeletal tissues, SMTE constructs are designed to ame-
liorate large tissue defects and can only have limited clinical
application without a vascular system to support the cellu-
lar component; similar considerations must be undertaken in
the case of preclinical constructs, as large three dimensional
structures have proven to replicate more closely the physiology
of the original tissues (Rouwkema et al., 2011). It is neces-
sary to mention that lesions occurring in craniofacial skele-
tal muscles (Garland and Pomerantz, 2012) must be set apart
from the previous generalizations, as these tissues present a dif-
ferent cellular milieu compared to the muscles of the limbs
and trunk (Kelly, 2010; Lemos et al., 2012); as such, it could
be argued that different models should be produced to study
these pathologies, though discipline may still prove of use for
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clinically applicable constructs due to the relatively restricted
size of the lesions and the difficult application of flaps in this
region.
SKELETAL MUSCLE STRUCTURE
The structure of skeletal muscle is inherently correlated to
its function; this tissue is characterized by a highly ordered
structure composed of parallel elements that can be sum-
marily divided in myofibrils, muscle fibers and fascicles. A
myofibril is the cytoplasmic molecular machinery capable
of actuating muscle contraction through the relative move-
ment of two interlocking macrostructures, the thin actin fil-
aments and thick myosin filaments (Huxley and Hanson,
1954). Myofibrils are bundled within the massive cytoplasm
of a multinucleated syncytium, the muscle cell or myofiber;
motoneuron connections in the cell membrane (the sar-
colemma) regulate the flow of calcium ions through the sar-
coplasmic reticulum, necessary for the contraction of the
myofibrils.
Myofibers constitute the parenchyma of skeletal muscle, and
are bundled in a complex ECM structure which connects them
to the muscle-tendon junction through three fibrous layers: the
endomysium, surrounding individual myofibers, the perimy-
sium, found over fascicles and the epimysium which cover the
entire muscle.
The fine structure is particularly evident in decellularizedmus-
cles, where the bare extracellular matrix (ECM) forms structures
not unlike bundles of flexible straws (Lieber and Fridén, 2000),
which is the principal component of the muscle’s anisotropic
response to stress (Takaza et al., 2013). Blood vessels run along
the fascicles in the perimysium and penetrate into the endomy-
sium, forming capillaries that project around the myofibers; due
to the elevated metabolic need of the skeletal muscle tissue, each
myofiber is connected to a capillary (Figure 1). At the same
time, the axons of motor neurons, which transmit the synap-
tic signal to the myofibers. Following the route traced by the
blood vessels, motor neurons terminate into neuromuscular junc-
tions in the proximity of sarcolemma-SR connections (triads);
the association between the vascular and the nervous system is
thought to start from the developmental phase of the organism
FIGURE 1 | Representative diagram of the skeletal muscle structure.
Connective layers and cell populations of particular interest are evidenced.
The biological components are not drawn to scale.
(Carmeliet and Tessier-Lavigne, 2005) and is conserved in regen-
erative processes involving a common mesenchymal progenitor
cell able to generate musculoskeletal, nervous and vascular tissues
(Tamaki et al., 2013).
The cellular machinery involved in the maintenance and
regeneration of skeletal muscle tissue is the same responsible for.
the delicate balance between hypertrophy and catabolism; these
processes has been studied in detail (Joe et al., 2010; Ten Broek
et al., 2010; Dellavalle et al., 2011; Turner and Badylak, 2012;
Saclier et al., 2013), and three cellular populations have proven
especially relevant to the regeneration process. SCs (Mauro,
1961), located between the basal lamina and the sarcolemma,
are the tissue resident progenitor cells responsible for the main-
tenance and the continual production on myoblasts. Once acti-
vated, SCs will reveal heterogeneity in their population and will
start dividing and producing muscle progenitor cells (MPCs)
that eventually will become myoblasts and fuse to the existing
myofibers (Boldrin et al., 2010); pathological conditions such as
Duchenne muscular dystrophy (DMD) are known to deplete the
reservoir of available SCs, leading to fibrosis and adipose tissue
inclusion in muscular tissues.
SC pools can be replenished by muscular tissue pericytes
(MPs), a population of cells found in close proximity to blood
vessels and difficult to identify, as they bear no unique CD set
or biochemical markers’ (Dellavalle et al., 2011). These cells
are capable of directing the behavior of endothelial cells (ECs),
acting as guides during the formation of new blood vessels
(Fuoco et al., 2014). Here, these cells have been shown to lose
in part their ability to differentiate into myogenic lineage and to
induce angiogenesis in nearby ECs as their host ages; neverthe-
less, the “myogenic/vasculogenic ability” appears to be restored
after the cells are seeded on a polyethylene glycol-fibrinogen
(PEG-F) surface. The mechanism underlying this behavior is
yet to be elucidated, although a comparison with previous
experiments by Discher et al. (2005) and Engler et al. (2006),
might suggest a sensitivity to the mechanical stimuli of cellular
environment.
Finally, fibro/adipogenic progenitors (FAPs) are a PDGFRα+
myogenic cell population, found in state of quiescence near blood
vessels, which activates in case of injury to the muscle (Joe et al.,
2010). FAP cells are known to promote the differentiation of
MPCs but do not have any capability to generate muscle tis-
sue on their own; on the contrary, they appear to be the main
source of the fibrotic and adipose tissues found in pathological
muscles (Uezumi et al., 2011). As such, these cells have been stud-
ied as a target for with microRNA (miRNA) treatments intended
to reduce the symptoms of the DMD syndrome through the
upregulation of the FAP cells myogenic programming, inducing
a “compensatory regeneration” (Mozzetta et al., 2013; Saccone
et al., 2014).
The interplay between these cell populations is fundamental
for the continuous renewal of skeletal muscle tissue, required
to compensate the damage occurring in day-to-day activities
(Järvinen et al., 2013); however, pathological states also require
the activation of the same cells in different processes that can
result in the regeneration of the tissue or the formation of a
fibrotic scar.
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SKELETAL MUSCLE REPAIR PROCESS
The regenerative process of muscle tissue is complex, and not
yet understood in its entirety; different cell populations interact
with each other and their environment to progress into out-
comes which span from the reestablishment of function to fibrosis
to pathological states of chronic inflammation (Koopman et al.,
2014). A brief recapitulation of the phases of this process and the
cellular populations involved will provide a background for the
in vivo implantation of SMTE constructs, and will define some
of the challenges involved in the development of in vitro devices.
Skeletal muscle regeneration can be summarily divided into three
overlapping phases: inflammation and activation of stem cells,
differentiation and deposition of a provisional ECM and finally
maturation of the tissues and remodeling of the ECM (Ciciliot
and Schiaffino, 2010).
In the first phase (the peak is reached in 2 h) of the regener-
ation process neutrophil granulocytes, innate immune response
cells with antimicrobial activity, enter the lesion from the blood
stream; their function is disputed but it has been proven that
they possess antimicrobial activity, exert phagocytosis on tissue
debris (Teixeira et al., 2003) and that they can stimulate vascu-
larization through production of VEGF-A (Christoffersson et al.,
2012); at the same time, however, this cell population releases
cytotoxic compounds that can interfere with the regeneration
process (Tidball and Villalta, 2010).
Another population of immune cells, the eosinophils, invade
the tissue in this phase and activate FAP cells through the
release of IL-4 (Heredia et al., 2013); after this initial stage the
macrophages enter the lesion site: pro-inflammatory CD68+
CD163− macrophages (M1), which reach maximal concentra-
tion 24 h after the injury, followed by a switch in polarization
leading to alternative activated, CD68− CD163+ macrophages
(M2) with anti-inflammatory activity (Tidball and Villalta, 2010;
Mantovani et al., 2013; Tidball et al., 2014). This activity bridges
the inflammatory-proliferative phase with the following one,
anti-inflammatory and differentiative; the shift is driven by the
interaction between the macrophages and the SCs, which activate
in response to the tissue injury and start an asymmetric replica-
tion cycle to produce myogenic progenitors (MP): simplistically,
it can be said that during the initial phase SC division is stimu-
lated by M1 macrophages via TNFα, then differentiation occurs
through IL-4 and IL-10 intervention by M2 cells. Whereas qui-
escent SC express a characteristic set of markers including Pax-7,
M-Cadherin and CD 34, activated SC rapidly change this con-
figuration as they proliferate; diminishing Pax -7 expression and
producing basic helix-loop-helix (bHLH) transcription factors as
they differentiate into committed MPs; these cells form multin-
ucleated myotubes that express neonatal MyHC (Tidball et al.,
2014). It is important to mention that only a fraction of the SC
population possesses stemness and is capable of perpetuate itself
and generate daughter cells of different phenotypes (Wang and
Rudnicki, 2012).
At the same time, FAP cells rapidly multiply under IL-4 stim-
ulation, enforcing an ambivalent role in the context of wound
healing: while they provide MPs with growth factors necessary
for their differentiation in myocytes, they are also the main ori-
gin of fibrosis in tissue repair and adipose tissue in pathological
conditions (Uezumi et al., 2011; Heredia et al., 2013). In parallel, a
population of connective tissue fibroblasts counterbalances FAPs’
activity by dampening SC differentiation through the formation
of a muscle connective tissue (MCT) and reciprocated paracrine
signals (Murphy et al., 2011).
The final phase in muscle regeneration there is the resolu-
tion of the provisional ECM and the formation of a definitive
structure that connects the stumps of the damaged fibers; in this
process the basal lamina acts as a guide for the growth of the
myofibers (Schmalbruch, 1976). The remodeling of the fibrotic
tissue and the subsequent regeneration of the skeletal muscle, or
lack thereof, is dependent on a variety of factors, including the
vascularization and the innervation of the healing area. Generally,
two positive outcomes can be envisioned as the resolution of the
third phase: the regeneration of the muscle tissue, with the origi-
nal architecture, or the formation of scar tissue and the separation
of the muscle fibers (Ciciliot and Schiaffino, 2010; Turner and
Badylak, 2012).
VASCULARIZATION
Vascular supply in the muscle is provided by a highly orga-
nized network of vessels, which are for the most part aligned
with the direction of the muscle fibers. The organization of the
structure is highly hierarchical an provides each myofiber with
blood supply; the primary arteries run along the direction of
the muscle fibers, and diverge inside the muscle through the
epimysium via feed arteries; those are short branches that pene-
trate inside the muscle at an angle, or perpendicularly. Secondary
arteriolar branches run again parallel to the muscle fibers, and
then arterioles, through the perimysium, and finally connect to
a microvascular unit composed of arterial and venous capillaries
that follows the endomysium.
SMTE constructs, as well as any other tissue engineering con-
struct which exceeds in any dimension the diffusion limit for
oxygen and nutrients (Karande et al., 2004; Griffith et al., 2005;
Radisic et al., 2006), require a specialized mean of delivery of such
substances and removal of metabolic byproducts if they are to
maintain the viability of seeded cells. Without these structures the
constructs are likely to form necrotic cores (Radisic et al., 2004),
compromising the regeneration process.
An arbitrary divide can be made between the techniques that
see the formation of vascular structures in vitro and those that
are implanted and develop vessels in vivo: in the first case vari-
ous avenues have been explored to generate patterns within the
volume of the engineered material so that the definitive shape of
the network will be informed beforehand, whereas in the second
case there is no specific structural conformation before implan-
tation. This discrimination is necessary as current techniques are
unable to producemature blood vessel networks in vitro, meaning
that a maturation process will always be present in the devel-
opment of such constructs, if they are to be used as implants.
Constructs intended as a vascularization models are subjected
instead to different degrees of maturation in vitro, which deter-
mine the characteristic of their vascular structures, and as such
will be discussed in the first group.
It can be argued that no engineered construct can be pro-
duced that will not incur into substantial remodeling upon
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implantation: even an hypothetical vascularized flap undistin-
guishable from the host’s tissue would be colonized and altered
by the surrounding capillaries, meaning that vascularization
of implanted devices will always comprise an in vivo phase.
According to this reasoning, the processes described here will be
grouped according to whether they focus on the production of
vascular structures within the constructs or the realization of con-
structs capable of allowing and increasing the penetration of the
host vessels upon implantation.
IN VITRO VASCULARIZATION
Approaches for in vitro vascularization focus on the produc-
tion and maturation of structured constructs before an eventual
implantation; this is realized by producing an environment favor-
able to the formation of vascular compartments by vasculogenic
cell populations, either by mechanical placement or through
directed self-assembly (Table 1).
Constructs belonging to the first group are arguably the most
numerous: they comprise those devices which implement struc-
tural and mechanical cues to direct the growth of vascular cells,
most often ECs, endothelial progenitor cells (EPCs) and vascu-
lar smooth muscle cells (VMSCs). The methods used to produce
the patterns include, most notably, sacrificial three-dimensional
patterns (Miller et al., 2012; Hooper et al., 2014), direct deposi-
tion of cellular suspensions (Kolesky et al., 2014), self-assembly of
polyelectrolyte solutions (Leong et al., 2013) or patterned cellular
sheets (Muraoka et al., 2013), and usage of decellularized scaf-
folds, although the best known example refers to cardiac tissue
(Ott et al., 2008; Koffler et al., 2011). In particular, the cell sheet
techniques recently developed (Haraguchi et al., 2012; Nagamori
et al., 2013; Sakaguchi et al., 2013; Sekine et al., 2013) resulted
in the production of in vitro vascularized tissues using culture
dishes coated with poly-N-isopropylacrylamide (PNIPAM) poly-
mer derivatives that are able to modify the cellular adhesion by
changing their hydrophilicity in a temperature range compatible
with cell survival (Yamato et al., 2007). Interestingly, the interpo-
sition of a collagen sheet traversed with microchannels parallel to
its surface through which was flowing medium was sufficient to
generate the growth of vascular structures. These results indicate
that ECs are able to respond to the mechanical cues generated
by shear stress in adjacent vessels, even if these vessels are simply
cavities in collagen; this is in accordance with findings in the field
of vascular tissue engineering (Feaver et al., 2013) which describe
the result of the mechanical stimulation on the phenotype of ECs.
The complex effects resulting from cyclic mechanical stimuli are
a valid tool in directing the behavior of vasculogenic cells and the
generation of blood vessels (Kilarski et al., 2009; Boerckel et al.,
2011), but the resulting vessels lack the order and pervasiveness
of the natural vasculature; a better understanding of the cellu-
lar response to mechanical stress is therefore necessary to obtain
mature, lifelike constructs.
On the other hand, devices that stimulate vascular growth
in vitro without offering a predetermined pattern are not as
common since scaffolds permitting unimpeded development of
vascular structures are typically hydrogels, whose plastic qualities
and wide range of possible biochemical and structural modifica-
tions make them more adapt for in vivo settings. Nonetheless,
similar scaffold have been used to obtain networks either from
preexistent structures (angiogenesis) (Chiu et al., 2012), or from
isolated precursors (vasculogenesis) (Raghavan et al., 2010),
demonstrating a better performance upon implantation com-
pared to non-prevascularized constructs. This is also true for non-
woven polymeric scaffolds, where the random structure of the
scaffold limits the control over the growth of vessels (Levenberg
et al., 2005); these devices have also profited from the applica-
tion of biologically-derived hydrogel coatings, which provided a
more permissive to vascular growth (Lesman et al., 2011; Sadr
et al., 2012). Finally, “spontaneous” in vitro vascularization is fun-
damental in engineering “myooids” (Dennis and Kosnik, 2000),
self-aggregated constructs based on the mixed muscle cell popu-
lation. These constructs are based on provisional ECM scaffolds
synthesized by the fibroblast population present in the extract
from minced muscle, and present a self-organizing vascular lay-
out derived from the EC and the SMC population (Carosio et al.,
2013).
Construct which do not present geometrically defined cues
for the vascular development such as these rely instead on the
vasculogenic properties of EPCs and their development in cor-
relation with VSMCs, myoblasts and fibroblasts to obtain a viable
network of vessels (Lesman et al., 2011; Alekseeva et al., 2014);
however, these networks are rapidly restructured in vivo, and sub-
stituted with mature vessel which conform to the structure of
the implant (Bae et al., 2012; Hanjaya-Putra et al., 2013). This
means that these implants will undergo a vascularization process
in vivo that will largely supersede the one completed in the in vitro
phase; in the case of more mature vessels, the construct will con-
nect to the existing vasculature in vivo through “wrapping and
tapping” anastomoses (Cheng et al., 2011); after this passage, the
construct will be replace with cells and matrix from the host’s tis-
sues, in an inflammation-like process requiring the chemotaxis of
progenitors cells (Roh et al., 2010).
IN VIVO VASCULARIZATION
The development of blood vessels in vivo takes advantage of the
host’s regenerative capabilities, which can be regulated varying
the cellular and chemical composition of the implanted device.
The different phases that follows implantation recapitulate, opti-
mally, those observed in regeneration, steering the wound healing
process from a fibrotic/scarring outcome to a functional one (de
Jonge et al., 2014).
While regenerative processes are necessary for the maturation
of the former constructs into functional tissue, the immedi-
ate reaction to the engineered device is fundamental for the
generation of a viable vessel network, since the in vivo vascu-
larization requires a delicate balancing of the different phases
of wound healing and regeneration following the implantation,
so to achieve the necessary chemotaxis of progenitor cells and
paracrine regulators without incurring in a state of prolonged
inflammation (Gurtner et al., 2008).
There are two main tools with which to achieve this goal: the
cellular component of the device and the structure and func-
tionalization of the scaffold. The cellular components have been
selected from autologous (Conconi et al., 2005), syngeneic, allo-
geneic (Corona et al., 2014) or xenogeneic (Kang et al., 2011)
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Table 1 | In vitro models of interest.
References Model Scaffold Construct type Relevant details
Salimath and García,
2014
C2C12 PEG-MAL hydrogel In vitro model 3D model; variable stiffness;
chemical functionalization
Egusa et al., 2013 Mouse BMMSC; C2C12 Fibrin on silicone In vitro model Differentiation due to mechanical
stimulation, myogenic medium
Morimoto et al., 2013 C2C12, primary mNSC Matrigel In vitro model Self tension, NMJ formation
Nunes et al., 2013 hPSC differentiated in
cardiomyocites
Autologous ECM; collagen In vitro model Self assembly; electrical stimuli;
wire structure
Palamà et al., 2013 C2C12 – In vitro model μtopography; LbL polyelectrolyte
on glass
Shah et al., 2013 Human masseter muscle
cells
Biodegradable bacteriostatic phosphate
glass fibers; collagen
In vitro model μpatterning; self contraction
Snyman et al., 2013 C2C12; pHMB Neutralized collagen I hydrogel In‘vitro model Self contraction; reproducibility
Wang et al., 2013 GFP-C3H myoblasts Fibrin gel In vitro model Laminin, agrin formation;
formation of NM receptors
Bian et al., 2012 Neonatal sprague-dawley
rat SM myoblasts
Matrigel-fibrin mesoscopically structured
hydrogel
In vitro model Self contraction; analysis of SM
networks; electrical stimuli
Hosseini et al., 2012 C2C12 μstructured gelatin methacrylate In vitro model μpatterning; size analysis;
electrical stimuli
Monge et al., 2012 C2C12 Patterned film (polyelectrolyte) In vitro model μpatterning; stiffness
modification
Sharples et al., 2012 Aged C2C12 (54x) Collagen In vitro model Self contraction; reduced
contractile force
Weist et al., 2012 Primary cells from F344
soleus
Self produced ECM In vitro model TGF-β1 effect evaluation; electrical
stimuli; self contraction into 3D
Elmer et al., 2011 C2C12; C3H10T1/2 Electrospun PS In vitro model Chemical functionalization;
μtopography
Li et al., 2011 Primary myoblasts from
C57/B6 mice; embryonic
fibroblasts from E13/CF1
mice
Self produced ECM; fibrin In vitro model Self contraction and generation of
3D structures; cocolture
Pennisi et al., 2011 C2C12 Collagen I In vitro model Mechanical conditioning, uniaxial
vs. multiaxial
van der Schaft et al.,
2011
H5V EC; C2C12 Collagen I; self produced ECM In vitro model Self contraction; cocolture; effect
of paracrine VEGF on
vascularization and alignment
Lam et al., 2009 Spreague-dawley rat
soleus SC
Self-produced ECM In vitro model μpatterning; self assembly into
3D (roll-up)
Riboldi et al., 2008 C2C12 Degrapol In vitro model μpatterning
Engler et al., 2004 C2C12; primary human
fibroblasts
Patterned polyacrylamide gel In vitro model Mechanoregulation; cellular
substrate
Dennis et al., 2001 Primary sprague-dawley
rat SC and FBs
Self produced ECM In vitro model Self contraction; self structuring
3D (roll up)
BMMSC: Bone Marrow Mesenchimal Stem Cell. EC, Endothelial Cell; FB, FibroBlast; GFP, Green Fluorescent Protein; hPSC, human Pluripotent Stem Cell; mNSC,
mouse Neural Stem Cell; NM, NeuroMuscular; NMJ, NeuroMuscular Junction; PEG-MAL, PolyEthylene Glycol-MALeimide; pHMB, primary Human MyoBlast; SC,
Satellite cells; SM, Skeletal Muscle.
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sources, and have been used directly or subsequently to genetic
modification intended to increase their effectiveness through aug-
mented expression of growth factors and cytokines (De Coppi
et al., 2005). As for the scaffold, its structure can retain chemical
signals and modify their local concentration, either geometrically
or by surface modification which bind and/or release these fac-
tors at a controllable rate; similarly, scaffold derived from the
decellularization of tissues are treated to minimize the immune
reaction of a xenogeneic host (Badylak, 2014). Moreover, the rate
of degradation, and the mechanical and topographical character-
istics of the scaffold modify the behavior of the surrounding cells
(Zhang et al., 2014), and therefore of the vascular compartment;
uniform, randomized geometry, such as interconnected pore net-
works, facilitate the vascularization process, without imparting
a definitive structure of the vascular compartment (Levenberg
et al., 2005). However, since a functional design is proved to
be advantageous in the integration of SMTE constructs (Koffler
et al., 2011), and given that the process of vascularization is inex-
tricably bound to the structural development of living tissues
(Tirziu and Simons, 2009; Lesman et al., 2010), it is reasonable
to assume that the presence of a defined architecture prior to
implantation will inform the structure of the resulting implant,
facilitating its integration in tissues characterized by a high degree
of anisotropy such as skeletal muscle (Takaza et al., 2013).
MECHANICAL AND PHYSICAL STIMULI
Cells are sensitive to mechanical and physical changes in their
environment, such as the bidimensional or tridimensional struc-
ture of the scaffold, its stiffness, or the presence of a voltage across
the culture medium; recently, the effect induced by these param-
eters on cellular behavior have been studied in vitro, in the hope
to obtain versatile tools for tissue engineering not subjected to
the drawbacks suffered by biochemical signals, namely difficult
application, limited availability and restrictive regulations.
The cellular mechanisms responsible for the translation of
these signals into complex behavior are still being studied, notably
in the engineering of tissues with load-bearing and dynamic func-
tions (Guilak et al., 2014). Cells are able to feel and interact with
their environment through specialized clusters of transmembrane
proteins forming focal adhesions (FAs) (Eyckmans et al., 2011).
These structures connect extracellular proteins and other surfaces
viable to attachment to the cytoskeleton, the complex system of
structural proteins that functions as an actuator of mechanical
actions and as a sensor to the environment (Discher et al., 2005),
translating its deformation into transcription factors headed for
the nucleus; moreover, this structure forms a mechanical connec-
tion the nucleus and the Golgi Apparatus to the exterior of the cell
(Wang et al., 2009), suggesting a close relationship between the
shape of nucleus and the behavior of the cell (Nava et al., 2014).
In particular, the cytoskeletal architecture of the skeletal mus-
cle is intrinsically related to its function and mediates the
mechanical stimuli required in the maturation of tissue engineer-
ing constructs (Vandenburgh et al., 1988, 1991, 1999). In the
original work of Vandenburgh et al. chicken myoblasts seeded
on a collagen gel were exposed to stimuli meant to simulate
processes observed in embryos, in accordance with the gen-
erally agreed principle that regeneration of tissue recapitulates
embryonic development (Chargé and Rudnicki, 2004); the pro-
tocol, with some variations (Boonen et al., 2010), consists in an
initial stretching corresponding to the elongation of the bone,
followed by intermittent contractions similar to the impulses
derived from postnatal stimuli (Riboldi et al., 2008). Skeletal mus-
cle cells exposed to the correct stimuli show increased expression
of differentiation markers compared to static cultures (Candiani
et al., 2010), and progress into the formation of polynucleate
syncytia; the reaction to cyclic strain, however, depends heavily
on the amplitude and frequency of the stimuli: the same line
of myoblasts have shown different reactions to alternate pro-
tocol and, interestingly, to alternate topographies. It has been
shown (Ahmed et al., 2010) that myoblast cell lines tend to align
to grooves in the substrate, but they respond to cyclic tension
by forming striates stress fibers angled at 45◦ with respect to
the direction of the deformation; finally, on flat surfaces, cyclic
mechanical stretching induces fiber angled ad 70◦ to the stretch-
ing axis, attributed to the perpendicular contraction due to the
Poisson’s ratio of the material. Given the complex behavior exhib-
ited by the cells in response to mechanical stimuli, a reliable
protocol for cellular alignment would prove of great value in the
engineering of tissues with specific geometric requirements (Li
et al., 2013b).
An interesting interpretation has been proposed recently
Equation (1) (Livne et al., 2014), which considers the dissipation
of cellular elastic energy as the principal reorientation factor The
resulting model predicts the orientation angle of the cells θ based
on a dimensionless parameter specific of the cell line and the ratio
between principal strain and the Poisson ratio of the support:
θ = arcos
(√
b+ 1 − 2b
r + 1
)
= arctan
(√
r + b · (1 − r)
1 − b · (1 − r)
)
(1)
where r is the negative inverse of the ratio between the principal
strain and its perpendicular counterpart, and b is a dimensionless
parameter that depends from the ratio between the cellular Young
modulus along its main orientation axis (Eθθ) and that along the
perpendicular axis (Eρρ). Although this model is capable of pre-
dicting the orientation angle well within a significant confidence
interval in a bidimensional setting, it is yet to be tested withmulti-
ple cell lines or in a three dimensional environment, a setting that
is known to influence cell behavior in a complex manner (Boonen
et al., 2010). Nevertheless, it provides a relatively straightforward
interpretative key to the disposition of cells in load bearing and
dynamic tissues, provided of course that the parameter b could be
used in cells with high aspect ratio such as myocytes.
While the disposition of the cells in response to mechanical
stimuli can be approximated to a purely physical process, growth,
differentiation and function are far more complex behaviors; a
viable avenue for this kind of research lies in the automated anal-
ysis of the cellular response to every possible combination of
multiple factors. This technique can provide a unifying research
framework and it can be used to rapidly individuate unexpected
cellular responses to specific sets of stimuli. Similar approaches
have been used to determine the reactions of undifferentiated cells
to 2D topography (Unadkat et al., 2011), biomaterial composi-
tion (Mei et al., 2010), stiffness in 3d scaffolds (Sala et al., 2011)
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and a combination of 3D scaffolds and growth factors (Ranga
et al., 2014). On a final note, it is worthwhile to mention that
these combinatorial studies are also limited in that they expose
the cell to repetitive stimuli that do not accurately replicate the
environment: the ECM is characterized by a controlled random-
ness, which has proven to influence cell behavior in bidimensional
studies (Dalby et al., 2006; Biggs et al., 2010); it can be argued then
that these studies can only provide a framework for the identifi-
cation of complex stimuli to be analyzed subsequently with more
accurate techniques.
CLINICAL APPLICATIONS—PRESENT AND FUTURE
As of now, SMTE constructs are either intended as in vitro
skeletal muscle disease models (Gayraud-Morel et al., 2009;
Vandenburgh, 2010; Kelc et al., 2013) (Table 1) or as in vivo pre-
clinical research tools (Turner et al., 2012; Carosio et al., 2013;
Mertens et al., 2014) (Table 2).
The only regenerative medicine devices to have reached clin-
ical application are acellular compounds derived from animal
ECM used in loco to improve the motility and strength of skeletal
muscles subjected to traumatic injury (Mase et al., 2010; Sicari
et al., 2014), or cell therapy strategies that are injected locally
and systematically to improve syndromes stemming from genetic
diseases (Tedesco et al., 2010; Tedesco and Cossu, 2012). While
these therapies use tissue engineering techniques, they do not fall
into the classic definition of TE constructs (Langer and Vacanti,
1993), since they lack either a cellular component or a scaffold
and are not subjected to maturation in a bioreactor. Nonetheless,
it is likely that future TE devices will refer to these forerunners as
a model on which to improve, and that further early approaches
in this field will implement methodologies that have proven most
effective on their own in clinical trials.
TOWARD A HUMAN HOST
In the translation to the clinic, TE devices face a unique set
of challenges due to their being artificial constructs made of
synthetic and biologic material, the latter being of autologous,
syngeneic or even xenogeneic origin (Mertens et al., 2014); setting
aside the regulatory aspects of this progression, which have been
recently described in details (Pashuck and Stevens, 2012; Fisher
and Mauck, 2013; Martin et al., 2014) there are some aspects
in the development of a preclinical engineered skeletal muscle
device that are of particular relevance when considering clinical
applications.
Most of the SMTE constructs that are currently being devel-
oped rely on small mammals as animal models to study their
effects on muscle repair (Table 2); these models are reliable, easily
available and provide comparable result between different labo-
ratories, yet they also suffer from substantial limitations in the
translation to the clinic (Boldrin et al., 2010; Seok et al., 2013;
Bareja et al., 2014). In most cases, human cell lines and pri-
mary cells are used to develop constructs that are subsequently
implanted in athymic models, lacking therefore the ability to
mount an adaptive immune response; these models allow for the
maturation of the implant in a living subject, under the reason-
ing that subsequent human trials would rely on autologous cells
and scaffolds proven to be clinically compatible. However, the
reaction to the human molecular apparatus found in the cellular
compartment of the devices may differ from that originating from
the host (Borisov, 1999). The predictive capability of these mod-
els in regard to cellular behavior under growth factor stimulation
was put into question in a recent paper (Mujagic et al., 2013),
where the authors suggested that the effects of different species’
isoforms of the growth factor VEGF vary greatly depending on the
recipient cells: this would explain the apparent inability of human
VEGF to cause angiomas inmousemodels, which could lead to an
underestimation of the side effects of modified cells in autotrans-
plantation cases. As a consequence, other studies which propose
the use of geneticallymodified cells to improve the vascularization
of regenerating muscles (Gianni-Barrera et al., 2013; Shevchenko
et al., 2013) may have to compensate the effects observed in ani-
mals as to avoid the formation of irregular vasculature in human
hosts; moreover, these uncertainties are also observed in clini-
cal cases involving novel combinations of accepted materials and
cellular populations, particularly undifferentiated staminal cells,
which, if unregulated, could lead to ectopic tissue formation and
neoplastic lesions (Amariglio et al., 2009; Thirabanjasak et al.,
2010).
There are currently few ways to solve this problem, as the
understanding of the interaction between host and implant is
still largely incomplete, particularly in regard to the role of the
immune system (Bohgaki et al., 2007); however, given the urgent
need for reliable constructs capable of supplementing and replac-
ing tissue transplants, alternative solutions to this problem could
be found in therapies that do away entirely with the cellular com-
ponent of the graft (Burdick et al., 2013), or in the development
of cellular populations such as autologous induced pluripotent
stem cells (iPSCs) (Takahashi and Yamanaka, 2006), which could
solve the problems correlated with allotransplantation (Araki
et al., 2013). Nevertheless, as these cells are capable of form-
ing teratomas (Knoeplfer, 2009), their usage in clinical setting
is problematic; protocols intended to produce differentiated cells
from iPSCs have proven effective in limiting the occurrence of
tumors both in mice (Liu et al., 2013; Suzuki et al., 2013) and in
non-primate models that more closely resemble human physiol-
ogy (Hong et al., 2014); as this line of research progresses, it will
be feasible to use this technology to develop constructs from the
patient’s own differentiated cells, in a clinical testing framework
offsetting potential benefits from limited risks (Goldring et al.,
2011).
Another topic that will need to be addressed before the clinical
application of SMTE constructs is also correlated to the immune
reaction to the devices and to the conditions present at the site
of implantation: these devices are in situ implants in recently
wounded sites which do not replicate the conditions of VML
encountered in clinical setting (Grogan et al., 2011; Li et al.,
2013a): it is not common practice to develop animal models of
VML in which the site of implantation had already undergone
a normal repair process which resulted in the formation of scar
tissue. As the homeostasis of the site of injury is much different
compared to that of uninjured tissues, the predictive value of the
animal models is diminished, and even more so when the dam-
age is compounded by genetic mutations leading to defects in the
repair process (Bosurgi et al., 2011).
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Table 2 | In vivo models of interest.
References Model Scaffold Construct type Relevant details
Corona et al., 2014 Heterologous MDCs BAM TA VML; Lewis rats Uniaxial mechanical strain
Juhas et al., 2014 GCaMP3+ Sprague-Dawley
muscle tissue
Fibrin/Matrigel In vitro model; dorsal
skinfold window chamber in
nude mice
Self contraction; in vitro
maturation; in vivo vascularization;
in vivo CTX damage regeneration
Carosio et al., 2013 Autologous muscle tissue Autologous ECM EDL VML; C57BL6 WT,
MLC/hAP
Self assembly, self contraction;
response to electrical stimuli;
vascularization
Corona et al., 2013a Autologous muscle tissue Autologous ECM TA VML; Lewis rats In vivo filler
Criswell et al., 2013 GFP-FVB MPCs; HUVECs;
10T1/2 cells
Matrigel Subcutaneous insertion in
nude mice
In vivo activity of ECs and
pericytes on SMTE constructs
Haraguchi et al., 2012 Rat cadiac cells; HUVECs;
HSMMCs
PNIPAAm substrate;
fibrin, gelatin
substrate; self
produced ECM
Subcutaneous dorsal
insertion, transplantation
onto infarcted heart in F344
nude mice
Cell sheet stacking; electrical
stimuli maturation; in vitro
vascularization
Williams et al., 2012 Explanted soleus muscle cells Autologous ECM on
fibrin
Implantation along the VL,
near the sciatic nerve.
Innervation with sural nerve
in F344
Self contraction and effect of
innervation with host’s nerve;
shift in myosin type
Koffler et al., 2011 C2C12; HUVECs; human
foreskin fibroblasts
Surgisis SIS Full thickness abdominal
wall replacement in nude
mice
Cocolture; variable in vitro
conditioning period
Levenberg et al., 2005 C2C12; HUVECs; mouse EFs PLLA-PGA porous
scaffold
Dorsal midline
subcutaneous implantation
in CB17 SCID
Coculture; prevascularization
Sicari et al., 2014 – SIS ATC (3), quadriceps (2) VML Clinical trial
Mase et al., 2010 – BAM Quadriceps femori VML Clinical case
BAM, Bladder Acellular Matrix; CTX, CardioToXin; EDL, Extensor Digitorum Longus; EF, Embryonic Fibroblasts; HSMMC, Human Skeletal Muscle Myoblast
Cells; HUVEC, Human Umbilical Vascular Endothelial Cell; MPC, Muscle Progenitor cell; PGA, PolyGlicolic Acid; PLLA, Poly-L-Lactic Acid; PNIPAAM, poly-N-
IsoPropylAcrylAmide; SIS, Small Intestine Submucosa; TA, Tibialis Anterior.
CURRENT APPROACHES
There are numerous hurdles to be overcome before SMTE con-
structs will have a use in clinical settings; to the best of our
knowledge, there have only been two clinical applications of
regenerative medicine devices for VML in skeletal muscle, both
involving in situ implantation of decellularized porcine small
intestinal submucosa (SIS). In the first instance, a clinical case,
a large volumetric defect in the quadriceps femori, treated 3
years before with a latissimus dorsi muscle flap (Mase et al.,
2010), was treated with an acellular SIS scaffold. Following the
positive outcome of this experiment a clinical trial involving
five patients and a different scaffold (porcine bladder matrix)
was recently published (Sicari et al., 2014), showing that the
treatment did not induce an adverse effect [as xenogeneic ECM
would if not completely decellularized (Keane et al., 2012)]
and improvement in strength and mobility in three cases, com-
pared to a patient-specific baseline. While this device cannot
be considered the result of tissue engineering according to the
usually accepted definition (Langer and Vacanti, 1993), it pro-
vides evidence that a commonly used tissue engineering scaf-
fold can improve skeletal muscle injuries; moreover, acellular
scaffolds such as SIS have shown performance comparable to
decellularized muscle tissue in SMTE treating of VML (De
Coppi et al., 2006; Wolf et al., 2012), which could obviate
the need for human tissue as a starting material for scaffold
development.
These results, and other reports analyzing the effect of empty
scaffolds on cell homing (Ju et al., 2014), suggest that SMTE
materials may indeed constitute a valid clinical options for the
treatment of VML. A better understanding of the role of the cel-
lular component of the devices will be required, as evidence in
other engineered tissues have proven a limited structural role for
the seeded cells, which are rapidly overcome and substituted by
the host’s own (Hibino et al., 2011).
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FUTURE DIRECTIONS
Tissue engineering and regenerative medicine treatment of skele-
tal muscle VML is intrinsically dependent on the dimensions of
the devices meant to substitute the missing tissues: the lesions
to be treated are extensive by their very own nature, and require
thick flaps that are beyond what is currently possible to repro-
duce through TE constructs. Given the unique characteristics of
skeletal muscle tissue, clinically relevant SMTE constructs will
require techniques aimed at the development of functional struc-
tures of large scale in the three dimensions. The techniques that
are going to see clinical application in the most immediate future
are those which are derived from accepted clinical methodologies,
which allow the introduction of fewer variables to be tested in the
preclinical phases.
In this respect, decellularized acellular devices possess many
characteristics that make them suitable for a rapid translation to
a clinical application: the ECM derived from large mammals has
seen ample use as grafts in vascular settings (Breymann et al.,
2009), and the structure and composition of the decellularized
material is capable of promoting the vascularization of the struc-
ture as it is assimilated in the body (Burdick et al., 2013; Teodori
et al., 2014); nonetheless, concerns about the complete decel-
lularization of the materials are still present, as residual traces
of cellular material can lead to the failure of the device (Keane
et al., 2012). An alternative to the use of heterologous mate-
rial is the production of in vitro ECM from cell cultures derived
from the host: this approach allows for less stringent decellu-
larization parameters, and provide a molecular milieu closely
resembling that of the original tissue, lacking however its highly
organized architecture, as these devices are produced with syn-
thetic scaffolds (Lu et al., 2011) or directly from connected cell
sheets (Dahl et al., 2011). For this methodology to be applica-
ble in VML treatment, the in vitro maturation should produce
either a single construct with patent vessels (Gualandi et al., 2013)
or multiple layers complete of vascular structure which would
anastomose when placed in close contact. The latter approach
has met with some results in recent reports (Sakaguchi et al.,
2013; Sekine et al., 2013), where multiple cell sheets have been
stacked to achieve multiple layer thickness to produce cellular
constructs that were directly implanted in animal models. While
the constructs obtained through this methodology are still far
from the requirements of skeletal muscle VML treatments, they
have been proven advantageous in the treatment of a case of
dilated cardiomyopathy (DCM) (Sawa et al., 2012); although the
dimensions of the implants (40mm of diameter and a thickness
of four cell layers) were scarcely comparable to those required for
VML, this case constitutes an important precedent for the appli-
cation of cell sheet engineering in the treatment of striated muscle
disorders.
Therefore, it is foreseeable that clinical SMTE will proceed
gradually incrementing the complexity of the implanted devices,
giving preference to methodologies that implement cellular pop-
ulations subjected to minimal in vitro treatment, or none at all.
CONCLUSIONS
SMTE has seen a rapid development in the last decade, facili-
tated by the growing understanding of the processes underlying
the regeneration of this tissue and the concomitant formation
of vascular networks. The latter topic is of particular interest for
the production of clinically relevant constructs, as the treatment
of VMLs requires large, mature engineered tissues with stable
vessel networks. The structure of the scaffold and mechanical
stimuli applied during the in vitro phase of development have
emerged as viable tools for the production of ordered, vascu-
larized tissues with significant prospective clinical applications.
As decellularized materials are undergoing clinical trials, it is
foreseeable that clinical devices composed of ordered scaffolds
and autologous vascular compartments will also be used in the
treatment of VMLs.
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